Mati Therapeutics Inc.
Mati Therapeutics is dedicated to developing innovative, non-invasive sustained drug delivery platforms for ocular diseases, aiming to improve patient outcomes and adherence to treatment. Their flagship Evolute® platform utilizes a proprietary punctal plug device to deliver medication continuously into the eye, offering a reliable alternative to eye drops. With a strong focus on ophthalmology, the company leverages extensive experience in the field to address unmet needs in eye care.
Industries
Nr. of Employees
small (1-50)
Mati Therapeutics Inc.
101 Colorado Avenue, Suite 2409, Austin TX 78701
Patents
Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US-11633300-B2
View DetailsDrug delivery methods, structures, and compositions for nasolacrimal system
US-11406592-B2
View Details
Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US-11633300-B2
View DetailsDrug delivery methods, structures, and compositions for nasolacrimal system
US-11406592-B2
View DetailsProducts
Punctal plug sustained ocular drug delivery system
A minimally invasive punctal plug device designed to retain in the nasolacrimal punctum and release medication continuously to the tear film via a tailored drug-eluting core for extended-duration ocular therapy.
Punctal plug sustained ocular drug delivery system
A minimally invasive punctal plug device designed to retain in the nasolacrimal punctum and release medication continuously to the tear film via a tailored drug-eluting core for extended-duration ocular therapy.
Services
Partnership arrangements to formulate and develop ophthalmic molecules for delivery via a punctal plug sustained-release platform, including access to preclinical and clinical development capabilities.
Partnership arrangements to formulate and develop ophthalmic molecules for delivery via a punctal plug sustained-release platform, including access to preclinical and clinical development capabilities.
Expertise Areas
- Ocular drug delivery
- Drug-device combination development
- Formulation and process development
- Clinical trial management (ophthalmology)
Key Technologies
- Punctal plug-based sustained drug delivery
- Drug-eluting core controlled-release formulations
- Hydrogel lacrimal implants
- Lyophilization
News & Updates
Mati announced its selection to present at the Ocular Innovation Summit in Chicago, showcasing its development of three new programs based on its Evolute® platform for ocular inflammation, pain, and glaucoma.
Mati announced that its international patent portfolio has grown to 114 issued patents, including a key U.S. patent for a hydrogel lacrimal implant for ophthalmic drug delivery, strengthening its competitive position.
Details about Mati's presentation at the Ocular Innovation Summit, focusing on its sustained drug delivery programs for eye care.
Information on the expansion of Mati's patent portfolio, including a significant U.S. patent for a hydrogel lacrimal implant.
Mati's patent portfolio has grown to 114 issued patents, including a key patent for a hydrogel lacrimal implant for drug delivery.
Mati announced its selection to present at the Ocular Innovation Summit in Chicago, showcasing its development of three new programs based on its Evolute® platform for ocular inflammation, pain, and glaucoma.
Mati announced that its international patent portfolio has grown to 114 issued patents, including a key U.S. patent for a hydrogel lacrimal implant for ophthalmic drug delivery, strengthening its competitive position.
Details about Mati's presentation at the Ocular Innovation Summit, focusing on its sustained drug delivery programs for eye care.
Information on the expansion of Mati's patent portfolio, including a significant U.S. patent for a hydrogel lacrimal implant.
Mati's patent portfolio has grown to 114 issued patents, including a key patent for a hydrogel lacrimal implant for drug delivery.